These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7277186)

  • 1. Antagonism of KW-5338 (domperidone) against emesis and depression of intestinal motility induced by L-DOPA.
    Shuto K; Shiozaki Z; Kojima T; Tanaka M
    J Pharmacobiodyn; 1980 Dec; 3(12):709-14. PubMed ID: 7277186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of KW-5338 (domperidone) on gastric motility.
    Shuto K; Shiozaki S; Kojima T; Tanaka M
    J Pharmacobiodyn; 1980 Dec; 3(12):715-9. PubMed ID: 7277187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs.
    Iwanaga Y; Miyashita N; Saito T; Morikawa K; Itoh Z
    Jpn J Pharmacol; 1996 Jun; 71(2):129-37. PubMed ID: 8835639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of reverse peristalsis of the intestine by domperidone.
    Ehrlein HJ
    Scand J Gastroenterol Suppl; 1981; 67():199-200. PubMed ID: 6941409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Domperidone: a peripherally acting dopamine2-receptor antagonist.
    Barone JA
    Ann Pharmacother; 1999 Apr; 33(4):429-40. PubMed ID: 10332535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Emetic and catalepsy-inducing actions of buflomedil].
    Koda H; Hashimoto T; Kuriyama K
    Nihon Yakurigaku Zasshi; 1988 Dec; 92(6):375-9. PubMed ID: 3250915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of three preclinical models for nausea and vomiting assessment.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly.
    Hanew K; Sasaki A; Sato S; Goh M; Yoshinaga K
    J Clin Endocrinol Metab; 1987 Feb; 64(2):255-60. PubMed ID: 3793848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of clebopride, domperidone, metopimazine, and trimebutine as antiemetics and inducers of gastrointestinal peristalsis].
    Berga P; Beckett PR; Massó JL; Roberts DJ
    Arch Farmacol Toxicol; 1981 Apr; 7(1):189-92. PubMed ID: 7198896
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential action of domperidone to modify emesis and behaviour induced by apomorphine in the ferret.
    Lau AH; Ngan MP; Rudd JA; Yew DT
    Eur J Pharmacol; 2005 Jun; 516(3):247-52. PubMed ID: 15963978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropharmacological comparison between domperidone and metoclopramide.
    Wauquier A; Niemegeers CJ; Janssen PA
    Jpn J Pharmacol; 1981 Jun; 31(3):305-14. PubMed ID: 7198163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.
    Brogden RN; Carmine AA; Heel RC; Speight TM; Avery GS
    Drugs; 1982 Nov; 24(5):360-400. PubMed ID: 6756878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excitatory response of gastric movement by domperidone and the mechanism involved.
    Fujii K; Takasugi S; Toki N
    Arzneimittelforschung; 1980; 30(4):640-4. PubMed ID: 7190407
    [No Abstract]   [Full Text] [Related]  

  • 15. Domperidone: review of pharmacology and clinical applications in gastroenterology.
    Reddymasu SC; Soykan I; McCallum RW
    Am J Gastroenterol; 2007 Sep; 102(9):2036-45. PubMed ID: 17488253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological studies on the clathrate compound of mobenzoxamine with beta-cyclodextrin. (I). Effects on the digestive system].
    Yokochi E; Kohno S; Ohata K
    Nihon Yakurigaku Zasshi; 1988 Nov; 92(5):297-310. PubMed ID: 3243512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine.
    Iwanaga Y; Miyashita N; Morikawa K; Mizumoto A; Kondo Y; Itoh Z
    Gastroenterology; 1990 Aug; 99(2):401-8. PubMed ID: 2365190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
    Lundblad M; Vaudano E; Cenci MA
    J Neurochem; 2003 Mar; 84(6):1398-410. PubMed ID: 12614340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Domperidone, a new dopamine antagonist.
    Champion MC; Hartnett M; Yen M
    CMAJ; 1986 Sep; 135(5):457-61. PubMed ID: 3527396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease.
    Camargo SM; Vuille-dit-Bille RN; Mariotta L; Ramadan T; Huggel K; Singer D; Götze O; Verrey F
    J Pharmacol Exp Ther; 2014 Oct; 351(1):114-23. PubMed ID: 25073474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.